TOLDBODGADE 33, 1253 COPENHAGEN K, G7
Reports on Form 6-K for August 2026
Capital Increase as a Result of Employee Warrant Exercise
Announces Financial Results for the First Half of 2026
Material disclosure
Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Reports Foreign Private Issuer Information for June 2026
Notification of Major Holdings
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Effectiveness Notice
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13D - Ownership Report
Amended Tender Offer Statement by Third Party
Registration Statement for Depositary Shares
Registration Statement for Depositary Shares, Issued upon Effectiveness
Registration Statement for Additional Securities of Certain Foreign Private Issuers, Filed Pursuant to Rule 462(b)